I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, ENWEI PHARMACEUTICAL (301331.SZ) released its annual report for 2024, reporting an operating income of 812 million yuan for the year, a year-on-year increase of 3.43%; the net profit attributable to shareholders of the listed company was 37.4975 million yuan, a year-on-year decrease of 56.56%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 34.7296 million yuan, a year-on-year decrease of 52.80%; the basic earnings per share were 0.3728 yuan/share. It is proposed to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares
